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ABSTRACT
The disulfiram and copper complex (DSF:Cu) has emerged as a potent 
radiosensitising anti-cancer agent. The ability of copper to stabilise DSF in a planar 
conformation and to inhibit DNA replication enzymes stimulated our investigation of 
the effect of DSF:Cu on cell cycle regulation. Flow cytometry and immunoblotting were 
used to assess the effect of DSF:Cu on cell cycle progression of the neuroblastoma cell 
line SK-N-BE(2c) and the glioma cell line UVW. Treatment with 0.1 and 0.3 μM DSF:Cu 
inhibited DNA synthesis in SK-N-BE(2c) and UVW cells, respectively. The increased 
potency of ionising radiation treatment induced by DSF:Cu and/or gemcitabine was 
determined by clonogenic assay. Treatment with 0.3 μM DSF:Cu resulted in greater 
radiation kill, exemplified by dose enhancement factor values of 2.64 and 2.84 in SK-
N-BE(2c) and UVW cells, respectively. Although DSF:Cu failed to sensitise S phase 
cells to irradiation, we observed that DSF:Cu radiosensitisation was potentiated by 
the S phase-specific cytotoxic drug gemcitabine. The efficacy of the combination 
treatment consisting of DSF:Cu, gemcitabine and ionising radiation was schedule-
dependent. Together, these results describe cell cycle specific radiosensitisation by 
DSF:Cu. The well-established toxicity profiles of DSF and gemcitabine should facilitate 
their evaluation as a combination treatment in patients undergoing radiotherapy.
INTRODUCTION
The dithiocarbamate disulfiram (DSF) has been used 
for several decades as a deterrent in the treatment of alcohol 
addiction [1]. Recently, the role of DSF in the treatment of 
cancer has been recognised although its mechanism of action 
has not been established. DSF has been shown to inhibit 
proteasome activity [2], angiogenesis [3], P-glycoprotein (P-
gp) [4] and aldehyde dehydrogenase [5, 6]. Furthermore, DSF 
generates oxidative stress through the inhibition of NF-κB 
activation [7], by inhibition of superoxide dismutase (SOD) 
[8] and as a result of its induction of an increase in the ratio 
of oxidised glutathione to its reduced form [9]. It has also 
been shown that copper is required for DSF cytotoxicity [10] 
and that DSF acts as a copper ionophore [11, 12]. Therefore, 
intracellular copper deposition could be cytotoxic through 
the generation of oxidative stress resulting from Fenton 
reactions [producing cupric ions and hydroxyl radicals] or 
through enzymatic inhibition by virtue of copper’s binding 
to peptidic bonds. Moreover, copper complexes have been 
shown to intercalate between the base pairs of DNA owing 
to their planar conformation [13-15]. These reports raise 
the possibility that copper confers upon DSF a favourable 
conformation for DNA intercalation, resulting in alteration to 
the structure of DNA and cell death. It has been suggested that 
DSF and its reduced form, diethyldithiocarbamate, inhibit 
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DNA synthesis through inhibition of DNA polymerase and 
ribonucleotide reductase [16, 17]. Finally, topoisomerase I, an 
enzyme whose activity relieves torsional stress generated at 
the replication fork during DNA replication, has been shown 
to be inhibited by DSF via binding to critical thiol residues 
[18]. A similar mechanism of inhibition of DNA synthesis has 
been reported for the nucleotide analogue gemcitabine which 
interacts with ribonucleotide reductase via cysteine [19].
Therefore, the cytotoxicity of the disulfiram and 
copper complex (DSF:Cu) may result from the generation 
of oxidative stress, inhibition of DNA replication or 
modulation of the activity of other critical cell regulatory 
pathways. Despite the multiplicity of potential targets, 
DSF-induced side-effects are reversible upon cessation of 
treatment and have been safely managed clinically since 
1948 [20, 21].
DSF and its dithiocarbamate derivatives have been 
shown to be radioprotectors as measured by increased 
survival in yeast [22], decreased clonogenic cell kill 
[23], a longer survival in mice [24] and by a reduction 
in lipid peroxidation and DNA damage [25]. In contrast, 
dithiocarbamate derivatives have been reported to be 
radiosensitisers as measured by increased tumour growth 
delay in mice [26], increased clonogenic cell kill [23, 
27-28] and by increased erythrocyte heamolysis [29]. 
However, these studies employed inappropriately high, 
hence clinically irrelevant, concentrations of DSF in 
experimental conditions uncontrolled for the presence of 
copper. Recently, we have shown that clinically pertinent 
concentrations of DSF:Cu sensitised tumour cells grown 
as monolayers, spheroids or xenografts to γ-radiation and 
radiopharmaceutical treatments [10]. The mechanism of 
radiosensitisation remains unknown. We hypothesised 
that DSF:Cu sensitised cancer cells to ionising radiation 
treatment via the modulation of cell cycle progression.
RESULTS
Proteasome-independent radiosensitisation by 
DSF:Cu
DSF:Cu enhanced the clonogenic cell kill induced 
by ionising radiation in SK-N-BE(2c) (Figure 1A) 
and UVW cells (Figure 1B). The IC
50
 values following 
irradiation decreased 2.64-fold or 2.84-fold in the 
presence of 0.3 μM DSF:Cu in SK-N-BE(2c) or UVW 
cells, respectively. The interaction between DSF:Cu 
and ionising radiation, as evaluated by isobologram 
analysis, was synergistic in SK-N-BE(2c) cells (Figure 
1C) and additive in UVW cells (Figure 1D). Crucially, 
we previously reported that Cu alone does not influence 
radiosensitivity [10].
It has been shown that DSF:Cu inhibits proteasome 
activity [2, 30]. However, in SK-N-BE(2c) and UVW 
cells, proteasome activity was not inhibited following 
radiosensitising treatment consisting of 0.3 μM DSF:Cu 
(Figure 1E). This suggested that proteasome inhibition 
was not required for radiosensitisation by DSF:Cu. 
Together, these results confirmed the previously reported 
radiosensitising property of DSF:Cu [10], but indicated 
that a mechanism other than proteasome inhibition 
is responsible. The absence of a correlation between 
proteasome activity inhibition by DSF:Cu and cytotoxicity 
has also been suggested by others [31].
DSF:Cu inhibits DNA synthesis
Both SK-N-BE(2c) and UVW cells were arrested in 
early S phase by thymidine treatment. Their synchronous 
progression through S phase following release from 
thymidine block was indicated by the increase in 
propidium iodide intensity over 8 h (Figure 2A). 
DSF:Cu inhibited S phase progression (Figure 2A) and 
bromodeoxyuridine (BrdU) incorporation (Figure 2B). 
For instance, 8 h following release from the thymidine 
block, the proportion of G
2
 cells that incorporated BrdU 
was decreased 4.5-fold (P<0.001) in SK-N-BE(2c) cells 
and 1.6-fold in UVW cells by treatment with DSF:Cu 
(Figure 2B).
Copper complexes have been shown to be cytotoxic 
via binding to DNA [13-15]. Moreover, it has been 
suggested that DSF:Cu is a planar molecule [32], raising 
the possibility that DSF:Cu impedes DNA replication via 
insertion between the base pairs of DNA. Accordingly, 
we tested whether DSF:Cu could interact with DNA 
using circular dichroism (CD). In contrast to the known 
DNA intercalator ethidium bromide (EtBr), DSF:Cu 
did not modify the helicity nor the base stacking of calf 
thymus-DNA, as indicated by the lack of modification 
of the negative and positive waves of the CD spectrum, 
respectively (Figure 2C). Furthermore, the stability of 
calf thymus-DNA was tested by thermal denaturation 
in the presence or in the absence of DSF:Cu in order to 
determine whether interaction between DSF:Cu and calf 
thymus-DNA could occur via a mechanism other than 
intercalation. In control conditions without DSF:Cu, both 
helicity (Figure 2D) and base stacking (Figure 2E) of the 
DNA helix were lost as temperature increased. In contrast 
to the consequence of EtBr treatment, the rate of loss of 
DNA conformation due to increasing temperature was 
unaffected by DSF:Cu (Figure 2D and 2E). These results 
suggested that interaction between DSF:Cu and DNA is 
unlikely and that an alternative mechanism is responsible 
for the inhibition of DNA synthesis by DSF:Cu. One 
possibility is a negative regulatory impact of DSF:Cu upon 
enzymes responsible for DNA synthesis.
DSF:Cu does not abrogate G2 arrest induced by 
ionising radiation
We next evaluated whether DSF:Cu affected cell 
cycle progression through the G
2
 phase of the cell cycle. 
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Figure 1: The effect of DSF:Cu on cellular radiosensitivity. SK-N-BE(2c) (A) and UVW cells (B) were exposed to 0.3 μM 
DSF:Cu for 24 h and irradiated at the start of exposure to DSF:Cu. Data are means ± SEM, n=3. The nature of the interaction between 
IR and DSF:Cu was evaluated by isobologram analysis using SK-N-BE(2c) (C) and UVW cells (D). (E) The effect of DSF:Cu on the 
chymotrypsin-like activity of the proteasome was evaluated. Data are means ± SEM, n=3. The independent t-test was used to compare the 
means of test groups with those of untreated control: *P<0.05; **P<0.01.
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Exposure to DSF:Cu for 12 h resulted in increased 
proportions of SK-N-BE(2c) and UVW cells in G
2
-
M from 30.5% to 34.5% and from 23.0% to 33.9% 
(P<0.01), respectively (Table 1), indicating G
2
 arrest. 
This conclusion was supported by the observed decrease 
in the level of expression of total CDK1 following 
treatment of SK-N-BE(2c) (P<0.001) or UVW cells with 
DSF:Cu (Figure 3A, 3B). Decreased CDK1 expression 
has previously been shown to prevent entry into mitosis 
[33, 34].
One of the hallmarks of the cellular response to 
ionising radiation is the activation of the G
2
 checkpoint 
prior to entry into mitosis. To determine whether 
radiosensitisation by DSF:Cu was due to the inhibition 
of G
2
 checkpoint activation following irradiation, the 
distribution of unsynchronised SK-N-BE(2c) and UVW 
cells throughout the phases of the cell cycle was assessed 
12 h after irradiation in the absence or in the presence of 
DSF:Cu. Irradiation alone resulted in the activation of 
the G
2
 checkpoint in unsynchronised SK-N-BE(2c) and 
UVW cells (Table 1), as indicated by increases in the G
2
-
M populations from 30.5% to 53.7% (P<0.05) and from 
23.0% to 56.1% (P<0.001), respectively. In comparison 
with irradiation alone, the G
2
-M populations, following 
irradiation in the presence of 0.3 μM DSF:Cu, were 
decreased from 53.7% to 40.4% in SK-N-BE(2c) cells and 
from 56.1% to 44.0% (P<0.01) in UVW cells (Table 1), 
indicating that DSF:Cu may inhibit irradiation-induced 
G
2
 arrest. The activation of G
2
 arrest was also evaluated 
by immunoblotting of ATM1981 and CDK115 (Figure 3). 
ATM1981 detects DNA damage in the form of double-
strand breaks (DSB) and activates the G
2
 checkpoint as 
well as DSB repair [35]. CDK115, a downstream effector 
of ATM1981, prevents entry into mitosis to allow for the 
repair of DNA damage [35]. The G
2
 checkpoint was 
activated following irradiation, as indicated by an increase 
in expression level of ATM1981 (P<0.05) and CDK115 
(P<0.001) in SK-N-BE(2c) and UVW cells (Figure 3B, 
3C). In comparison with irradiation alone, expression of 
ATM1981 was unaltered by irradiation in the presence of 
DSF:Cu (Figure 3C), suggesting that DSF:Cu does not 
affect DSB detection following irradiation. In contrast, 
expression of CDK115 was reduced (P<0.001) following 
irradiation in the presence of DSF:Cu in comparison with 
Figure 2: The effect of DSF:Cu on DNA synthesis. Following release from thymidine block, synchronised SK-N-BE(2c) and 
UVW cells were exposed for 8 h to 0.3 or 0.1 μM DSF:Cu, respectively. The effect of DSF:Cu on DNA synthesis was monitored by flow 
cytometric analysis of propidium iodide-stained (A) or BrdU-stained (B) synchronised cells. The data are representatives of triplicate 
determinations. The proportions of BrdU-positive cells in G
2
 are means ± SEM, n=3. Independent t-test: *** P<0.001. (C) The interaction 
between DSF:Cu and DNA was investigated by circular dichroism (CD) using treatment with ethidium bromide (EtBr) as a positive control. 
(D, E) The effect of DSF:Cu on the stability of the DNA molecule in response to heat treatment was investigated by CD. The absolute CD 
values at 245 nm (D, nadir of the negative wave) and at 275 nm (E, zenith of the positive wave) were plotted against temperature to measure 
change in helicity and base stacking, respectively.
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irradiation alone (Figure 3B). However, the decrease in 
CDK115 expression is likely due to a decrease in total 
CDK1 expression.
We reasoned that if DSF:Cu suppressed the 
phosphorylation of CDK1 at tyrosine 15 as well as 
reducing the expression level of total CDK1, the levels of 
total CDK1 may be too low to trigger the mitotic process. 
Consequently, we anticipated that the apparent inhibition 
of the irradiation-induced G
2
 arrest may not be due to a 
bypass of G
2
 arrest but, instead, to the failure to complete 
S phase before entry into G
2
. Therefore, we studied cell 
cycle progression using synchronised populations of 
Table 1: The effect of DSF:Cu and ionising radiation on cellular accumulation at the G2 checkpoint.
Control DSF:Cu 5 Gy DSF:Cu + 5 Gy
SK-N-BE(2c) 30.5 ± 0.63 34.5 ± 1.63 53.7 ± 5.05* 40.4 ± 0.51¶
UVW 23.0 ± 0.83 33.9 ± 2.57** 56.1 ± 1.40*** 44.0 ± 0.50††¶¶
The percentages of unsynchronised SK-N-BE(2c) and UVW cells in G2-M, 12 h after irradiation and exposure to 0.3 μM 
DSF:Cu, were determined by FACS analysis of propidium-iodide-stained cells. Data are means ± SEM, n=3. One-way 
ANOVA with Bonferroni correction was used to compare the means of the test groups with those of the untreated control 
(*), with those of the irradiated group (†) or compared with those treated with DSF:Cu alone (¶). One symbol: P<0.05; two 
symbols: P<0.01; three symbols: P<0.001.
Figure 3: The effect of DSF:Cu on the phosphorylation of ATM and CDK1 induced by ionising radiation. (A) The 
expression levels of ATM and ATM1981 were determined by immunoblotting 1 h following irradiation whereas CDK1 and CDK115 expression 
levels were determined 12 h following irradiation. SK-N-BE(2c) and UVW cells were exposed to 0.3 μM DSF:Cu and irradiated with 5 Gy 
at the start of exposure to DSF:Cu. The immunoblots are representative examples of triplicate determinations. (B, C) Histogram data are 
fold changes in expression levels above background compared with untreated controls and normalised to the loading control β-actin. Data 
are means ± SEM, n=3. One-way ANOVA with Bonferroni correction was used to compare the means of the test groups with those of the 
control (*) or with those of the irradiated group (†). One symbol P<0.05, two symbols P<0.01; three symbols P<0.001.
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SK-N-BE(2c) and UVW cells. Synchronised cells were 
irradiated at the S-G
2
 border and immediately exposed to 
DSF:Cu. Cell cycle profiles were obtained 6 h after the 
commencement of irradiation and DSF:Cu treatments. 
At this timepoint, 30.5% of untreated SK-N-BE(2c) 
cells and 86.5% of untreated UVW cells had reached 
G
1
, indicating progress through G
2
 and mitosis (Table 2). 
In comparison, there were fewer SK-N-BE(2c) (17.2%, 
P<0.001) and UVW (4.6%, P<0.001) cells in G
1
 following 
DSF:Cu treatment alone (Table 2). The decrease in the 
proportion of cells in G
1
 following DSF:Cu treatment was 
accompanied by an increase in the proportion of SK-N-
BE(2c) and UVW cells in G
2
, indicating failure to progress 
through mitosis (Table 2). These results corroborated 
the observation made in Table 1 that DSF:Cu causes 
arrest in G
2
.
Irradiation at the S-G
2
 border increased the 
proportion of SK-N-BE(2c) (P<0.05) and UVW 
(P<0.001) cells in G
2
 (Table 2). The increase in the 
proportion of cells in G
2
 following irradiation was 
accompanied by a decrease in the proportion of both SK-
N-BE(2c) (P<0.001) and UVW (P<0.001) cells in G
1
. 
There was no inhibition of irradiation-induced cellular 
accumulation in G
2
 by DSF:Cu, indicated by similar 
proportions of cells in G
2
 and G
1
 in the irradiated group 
and in the group irradiated in the presence of DSF:Cu 
(Table 2). These observations indicated the failure of 
synchronised cells to bypass the irradiation-induced G
2
 
arrest in the presence of DSF:Cu.
Taken together, these results indicated the ability of 
DSF:Cu treatment to cause accumulation of cells in G
2
 and 
to inhibit DNA synthesis. The apparent prevention of the 
irradiation-induced accumulation of unsynchronised cells 
in G
2
 by DSF:Cu (Table 1) is likely due to a cytostatic 
effect of DSF:Cu on cell cycle progression through S 
phase.
Enhancement of cellular radiosensitivity by 
combination of DSF:Cu with the nucleotide 
analogue gemcitabine
Our results indicate that DSF:Cu is a radiosensitiser 
and that it inhibits DNA replication. However, the 
radiosensitivity of cells in S phase relies on a moving 
replication fork for the creation of lethal DSB in DNA 
[36]. Therefore, the radiosensitivity of S phase cells was 
evaluated in the presence of DSF:Cu. A clonogenic cell kill 
of 55% was achieved by irradiating unsynchronised SK-
N-BE(2c) cells with 3 Gy whereas 2 Gy was sufficient to 
achieve the same kill in SK-N-BE(2c) cells synchronised 
in early S phase (Figure 4A). Similarly, 40% kill of UVW 
clonogens was achieved by irradiating unsynchronised 
UVW cells with 3 Gy whereas 1 Gy was sufficient to 
achieve the same kill of UVW cells synchronised in early 
S phase (Figure 4B). These observations indicated that 
cells in early S phase are more sensitive to irradiation 
than unsynchronised populations. DSF:Cu radiosensitised 
SK-N-BE(2c) cells in S phase to a lesser degree than 
unsynchronised cells (P<0.01) whereas DSF:Cu failed to 
radiosensitise UVW cells in S phase (P<0.001) (Figure 4). 
These data indicated the resistance of cells in S phase to 
combination treatment consisting of ionising radiation and 
DSF:Cu.
Gemcitabine is a nucleotide analogue which kills 
cancer cells specifically in S phase. DSF:Cu has been 
shown to enhance gemcitabine efficacy through the 
inhibition of NF-κB [37], the generation of oxidative 
stress [38] or the eradication of aldehyde dehydrogenase-
positive cancer cells [5, 6, 39]. Since S phase cells showed 
resistance to treatment consisting of ionising radiation 
and DSF:Cu, we hypothesised that gemcitabine treatment 
could increase its efficacy by targeting S phase cells. In 
view of the fact that gemcitabine toxicity to S phase cells 
Table 2: The effect of DSF:Cu and ionising radiation on the progression of synchronised cells through G2.
Control DSF:Cu 5 Gy DSF:Cu + 5 Gy
SK-N-BE(2c)
G1 30.5 ± 0.70 17.2 ± 0.27*** 16.0 ± 0.79*** 17.2 ± 0.12***
S 18.8 ± 0.31 28.4 ± 0.48*** 17.0 ± 1.10 28.3 ± 0.76***
G2 33.7 ± 0.40 39.2 ± 0.62 42.4 ± 3.15* 37.3 ± 1.09
UVW
G1 86.5 ± 0.18 4.6 ± 0.70*** 13.2 ± 1.49*** 5.1 ± 0.12***
S 2.4 ± 0.08 1.2 ± 0.06 1.6 ± 0.06 1.8 ± 0.53
G2 9.6 ± 0.33 93.8 ± 0.79*** 84.3 ± 1.62*** 92.8 ± 1.65***
The percentages of synchronised SK-N-BE(2c) and UVW cells in G
1
, S and G
2
 were determined by FACS analysis of 
propidium-iodide-stained cells 6 h after irradiation at the S-G
2
 border and treatment with 0.3 μM DSF:Cu. Data are means 
± SEM, n=3. One-way ANOVA with Bonferroni correction was used to compare the means of the test groups with those of 
the untreated control (*). One symbol: P<0.05; two symbols: P<0.01; three symbols: P<0.001.
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depends on its incorporation into DNA and that DSF:Cu 
inhibits DNA synthesis, we hypothesised that modulation 
by gemcitabine of the efficacy of the treatment consisting 
of ionising radiation and DSF:Cu may be schedule-
dependent. Preliminary investigations indicated that Cu 
does not influence the sensitivity of SK-N-BE(2c) nor 
SH-SY5Y cells to gemcitabine treatment (Supplementary 
Figure 1).
Exposure of SK-N-BE(2c) or UVW cells 
to gemcitabine for 24 h inhibited DNA synthesis, 
indicated by a significant decrease in the proportion 
of cells incorporating BrdU (P<0.001) (Figure 5A and 
5C). However, in SK-N-BE(2c) cells, BrdU positivity 
significantly increased from 1.4 ± 0.2 to 62.4 ± 1.6 % 
(P<0.001) 8 h after removal of gemcitabine from the 
medium, indicating the reversible nature of the inhibition 
of DNA synthesis in SK-N-BE(2c) cells by gemcitabine 
(Figure 5A). In UVW cells, although BrdU positivity 
significantly increased from 2.4 ± 1.2 to 14.0 ± 0.1 % 
(P<0.05) 8 h following removal of gemcitabine from the 
medium, there was no increase in BrdU-positive cells 
from 4 to 8 h, indicating that DNA synthesis did not restart 
within 8 h of removal of gemcitabine (Figure 5C). Pre-
treatment of unsynchronised SK-N-BE(2c) and UVW 
cells with gemcitabine for 24 h before exposure to DSF:Cu 
for 8 h (schedule 1) resulted in increased radiation DEF 
values in comparison with treatment with gemcitabine or 
DSF:Cu alone (Figure 5B, 5D, Table 3). The nature of the 
interaction between DSF:Cu, gemcitabine and irradiation 
was evaluated by combination index (CI) analysis. 
Synergism was indicated by CI values less than 1 at 
toxicity levels greater than 0.5 in SK-N-BE(2c) cells and 
greater than 0.25 in UVW cells (Table 4). These results 
indicated that re-initiation of DNA synthesis following 
removal of gemcitabine from the culture medium in SK-
N-BE(2c) cells, but not in UVW cells, did not affect the 
efficacy of drug administration according to schedule 1.
Next, the efficacy of alternative schedules of 
drug administration was evaluated. Pre-treatment of 
unsynchronised SK-N-BE(2c) and UVW cells for 8 h 
with DSF:Cu followed by exposure to gemcitabine for 
24 h (schedule 2) resulted in increased radiation DEF 
values in comparison with treatment with gemcitabine 
or DSF:Cu alone (Figure 6A, 6C, Table 3). Synergism 
was indicated by CI values less than 1 at toxicity levels 
greater than 0.5 in SK-N-BE(2c) and UVW cells (Table 
4). The simultaneous treatment with gemcitabine, DSF:Cu 
and ionising radiation (schedule 3) resulted in increased 
radiation DEF values in comparison with treatment with 
gemcitabine or DSF:Cu alone in SK-N-BE(2c) cells 
(Figure 6B, Table 3), but not in UVW cells (Figure 6D, 
Table 3). Accordingly, synergism was observed only in 
SK-N-BE(2c) cells as indicated by CI values less than 1 at 
toxicity levels greater than 0.5 (Table 4).
The nature of the interaction between ionising 
radiation, DSF:Cu and gemcitabine was further evaluated 
in the neuroblastoma cell line SH-SY5Y and the glioma 
cell line T98G. In agreement with the observations 
made using UVW cells, the simultaneous treatment with 
gemcitabine, DSF:Cu and ionising radiation (schedule 3) 
resulted in an antagonistic interaction in SH-SY5Y and 
T98G, as indicated by CI values greater than 1 (Table 4). 
Figure 4: The effect of DSF:Cu on cellular radiosensitivity in S phase. (A) Unsynchronised SK-N-BE(2c) cells were irradiated 
with 3 Gy in the absence or the presence of 0.15 μM DSF:Cu. Alternatively, following synchronisation, SK-N-BE(2c) cells were irradiated 
at the start of S phase with 2 Gy in the absence or the presence of 0.15 μM DSF:Cu. Data are means ± SEM, n=3. (B) Unsynchronised 
UVW cells were irradiated with 3 Gy in the absence or the presence of 0.1 μM DSF:Cu. Alternatively, following synchronisation, UVW 
cells were irradiated at the start of S phase with 1 Gy in the absence or the presence of 0.1 μM DSF:Cu. Data are means ± SEM, n=3. One-
way ANOVA with Bonferroni correction was used to compare the means of the combination treatment with those treated with either single 
agent (a, P<0.001; b, P<0.01, c, non-significant). The independent t-test was used to compare the means of the combination treatment in 
unsynchronised cells versus those of S phase cells (**P<0.01).
Oncotarget65907www.impactjournals.com/oncotarget
For both alternate schedules 2 and 3, there was a trend 
towards an additive interaction between gemcitabine, 
DSF:Cu and ionising radiation in SH-SY5Y and T98G 
at toxicity levels greater than 0.75 (Table 4). However, 
pre-treatment of SH-SY5Y with DSF:Cu and ionising 
radiation prior gemcitabine treatment (schedule 2) did 
not result in an additive interaction despite CI values 
decreasing towards additivity with increasing toxicity 
levels (Table 4).
Since others have shown that the enhancement 
of gemcitabine cytotoxicity by DSF:Cu may be due 
to the generation of oxidative stress, we hypothesised 
that the difference in sensitivity to schedule 3 of drug 
administration between SK-N-BE(2c) and UVW cells 
may be due to their relative sensitivity to oxidative stress. 
It has also been shown that DSF induces the formation of 
reactive oxygen species (ROS) [5, 40]. In these studies, 
the generation of ROS following exposure of cells to 
Figure 5: The effect of drug administration according to schedule 1 on clonogenic survival of SK-N-BE(2c) and UVW 
cells. (A, C) Unsynchronised SK-N-BE(2c) and UVW cells were exposed, for 24 h, to 450 nM or 20 nM gemcitabine, respectively. These 
concentrations of gemcitabine corresponded to their IC
50
 values. The ability of SK-N-BE(2c) and UVW cells to incorporate BrdU into the 
DNA was measured by flow cytometry 0, 4 and 8 h following removal of gemcitabine from the culture medium. The data are representative 
examples of triplicate determinations. The proportions of BrdU-positive cells are means ± SEM, n=3. One-way ANOVA with Bonferroni 
correction was used to compare the means of the test groups with those of the control (*) or with those of group treated with gemcitabine 
at the 0 h time-point (†). One symbol P<0.05, 3 symbols P<0.001. (B, D) Schedule 1 consisted of pre-treatment of cells with gemcitabine 
for 24 h immediately followed by treatment with DSF:Cu for 8 h. The cells were irradiated at the commencement of exposure to DSF:Cu. 
Data are means ± SEM, n=3.
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DSF:Cu was prevented by treatment with the ROS 
scavenger N-acetyl cysteine (NAC) [5, 40]. Therefore we 
tested the sensitivity of SK-N-BE(2c) and UVW cells to 
schedule 3 in the absence and in the presence of the ROS 
scavenger NAC. However, since DSF interacts with thiols, 
the putative increased survival resulting from the presence 
of NAC may be due to direct interaction between NAC 
and DSF:Cu and not to the scavenging of ROS. Therefore, 
we also tested our hypothesis using the antioxidant Tiron 
whose mechanism of action is independent of thiol 
interaction [41]. We observed that the toxicity to SK-N-
BE(2c) cells of schedule 3 treatment was reduced 10-fold 
(P<0.01) by treatment with 1 mM NAC or Tiron (Figure 
7A). In contrast, NAC or Tiron failed to enhance the 
survival of UVW cells subjected to combination treatment 
using schedule 3 (Figure 7B). The enhanced kill of SK-N-
BE(2c) cells, but not of UVW cells, induced by schedule 
3 treatment may be due to a greater oxidative stress 
generated in SK-N-BE(2c) cells. In turn, the heightened 
sensitivity of SK-N-BE(2c) cells to oxidative stress may 
explain the synergistic interaction observed between 
ionising radiation and DSF:Cu in comparison with the 
additive interaction observed in UVW cells (Figure 1B, 
1D). Alternatively, UVW cells may express higher levels 
of antioxidants or repair DNA more efficiently.
DISCUSSION
In summary, we report that DSF:Cu treatment 
sensitised cancer cells to ionising radiation via a 
mechanism independent of proteasome activity. The 
effects of DSF:Cu on cell cycle progression were manifest 
by inhibition of DNA synthesis, CDK1 depletion and 
blockade of entry into mitosis. Finally, the failure to 
radiosensitise cells in S phase by DSF:Cu was overcome 
by gemcitabine treatment in a cell-dependent and 
schedule-dependent manner. The cell cycle-specific effects 
of DSF:Cu and the strategy to enhance radiosensitisation 
by DSF:Cu are summarised in Figure 8.
Following exposure to stress, such as radiation, NF-
κB is activated by phopsphorylation-induced proteasomal 
degradation of its inhibitor IkB [42]. NF-κB activation 
has been associated with radioresistance [43], notably 
via induction of anti-apoptotic and antioxidant gene 
expression [44, 45]. Furthermore, DSF has been shown to 
inhibit the proteasome [2] and NF-κB activation [7]. We 
have previously shown that specific proteasome inhibition, 
using bortezomib, is a potent radiosensitising strategy [46, 
47]. However, in the present study, radiosensitisation by 
DSF:Cu could not be assigned to proteasome inhibition. 
Since NF-κB activation requires proteasomal activity, our 
data suggest that NF-κB inhibition is not the mechanism 
by which DSF:Cu sensitises cancer cells to ionising 
radiation.
We report that treatment with DSF:Cu reduced 
CDK1 expression levels, caused a G2 arrest and 
the failure to enter mitosis. CDC25 phosphatase is 
responsible for the dephosphorylation and activation 
of CDK1, which leads to progression through mitosis. 
CDC25 phosphatase contains a cysteine residue (C473) 
involved in its catalytic domain [48]. Given the ability of 
DSF to form disulfide bonds, a possible scenario is the 
formation of a mixed disulfide between DSF and C473 
of CDC25. The resulting sustained phosphorylated state 
of CDK1, in conjunction with reduced levels of CDK1, 
prevents progression through mitosis and promotes 
accumulation of cells in G2. CDK1 is also an effector 
of S phase checkpoint activation following treatment 
with DNA damaging agents such as cisplatin and 
ionising radiation [34]. It follows that CDK1 depletion 
by DSF:Cu cannot explain inhibition of DNA synthesis. 
Interestingly, many DNA replication enzymes contain 
Table 3: Radiation dose enhancement values at the 90% toxicity level.
DSF:Cu Gemcitabine DSF:Cu + gemcitabine
SK-N-BE(2c)
Schedule 1 1.59 ± 0.34 2.48 ± 0.28 2.97 ± 0.43
Schedule 2 1.64 ± 0.45 1.42 ± 0.09 2.59 ± 0.49
Schedule 3 2.39 ± 0.49 2.29 ± 0.19 4.50 ± 0.83
UVW
Schedule 1 1.45 ± 0.35 2.17 ± 0.24 3.35 ± 0.35
Schedule 2 1.32 ± 0.26 1.41 ± 0.09 2.06 ± 0.45
Schedule 3 0.88 ± 0.19 1.15 ± 0.49 0.94 ± 0.05
The linear-quadratic equation was used to calculate the radiation dose enhancement factor at the 90% toxicity level 
following treatment with DSF:Cu, gemcitabine and ionising radiation according to administration schedules 1, 2 and 3. For 
SK-N-BE(2c) cells, the DSF:Cu and gemcitabine concentrations were 0.15 μM and 450 nM, respectively. For UVW cells, 
the DSF:Cu and gemcitabine concentrations were 0.1 μM and 20 nM, respectively. Data are means ± SEM, n=3.
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iron-sulfur clusters or thiol residues susceptible to mixed 
disulfide formation with DSF [49, 50]. Furthermore, 
the thiol-containing small molecules glutathione, 
glutaredoxin and thioredoxin are required to supply 
electrons to ribonucleotide reductase in order to convert 
ribonucleotides into deoxyribonucleotides for DNA 
synthesis [51]. It has also been reported that non-protein 
thiol levels increase during S phase [52]. Therefore, by 
virtue of DSF’s ability to form mixed disulfides with 
cellular components [53], the interaction of DSF:Cu with 
thiol-containing molecules may explain its inhibitory 
action on DNA synthesis.
It has been reported that CDK1 depletion leads to 
sensitisation of S phase cells to DNA damaging agents 
such as cisplatin and ionising radiation [34]. However, 
our observation that DSF:Cu depleted CDK1 levels but 
failed to sensitise S phase cells to irradiation precludes 
CDK1 depletion as the mechanism for DSF:Cu-induced 
radiosensitisation. Instead, the lack of sensitisation 
of S phase cells to ionising radiation by DSF:Cu was 
attributed to the inhibition of DNA replication. This 
hypothesis is consistent with reports suggesting that 
the mechanism of radiation-induced cell kill in S phase 
is dependent on a progressing replication fork, which, 
upon collision with radiation-induced DNA single strand 
breaks (SSB), generates lethal DSB. For instance, it has 
been shown that the collision of the replication fork 
with SSB created by treatment with topotecan generates 
lethal DSB which synergises with ionising radiation [54]. 
Similarly, radiosensitisation by olaparib, an inhibitor of 
SSB repair, was enhanced in populations synchronised 
in S phase and abrogated by concomitant exposure to the 
DNA polymerase α inhibitor aphidicolin [36].
Gemcitabine is a known radiosensitiser through the 
following hypothetical mechanisms. As a prodrug, the 
nucleoside analogue gemcitabine requires phosphorylation 
by deoxycytidine kinase (dCK) for its incorporation 
into DNA. It has been reported that ionising radiation 
increases dCK expression and activity in a dose- and time-
dependent manner [55]. Secondly, it has been suggested 
that gemcitabine is a radiosensitiser through the inhibition 
of ribonucleotide reductase-mediated supply of dATP 
for DNA repair [56] and through the accumulation of 
cells in early S phase, a radiosensitive phase of the cell 
cycle [57]. However, it has been shown that glutathione 
confers upon cancer cells resistance to gemcitabine [58]. 
Therefore, increased oxidative stress resulting from 
the interaction between DSF:Cu and glutathione [53] 
could sensitise cancer cells to gemcitabine treatment. In 
preclinical studies, DSF, and its derivative pyrrolidine 
dithiocarbamate, have been successfully used to enhance 
the efficacy of gemcitabine, notably through NF-κB 
inhibition and generation of oxidative stress [5, 37, 38]. 
Alternatively, DSF:Cu has been shown to inhibit ALDH 
activity [5, 39, 40], the formation of tumorspheres in vitro 
[5] and the growth of ALDH-positive xenografts in vivo 
[6], indicating the toxicity of DSF:Cu to cancer stem 
cells. We cannot speculate whether enhancement of 
toxicity by the combination of DSF:Cu, ionising radiation 
and gemcitabine is mediated by ALDH inhibition and 
the depletion of cancer stem cells because, in our study, 
we cultured our cells in conditions not optimised for 
cancer stem cell enrichment. We complement these 
Table 4: Combination indices describing the nature 
of the interaction between gemcitabine, DSF:Cu and 
ionising radiation
SK-N-BE(2c)
Affected 
fraction
Schedule 1 Schedule 2 Schedule 3
0.25 2.67 2.49 2.54
0.5 1.37 1.33 1.31
0.75 0.82 0.81 0.81
0.95 0.42 0.42 0.46
UVW
Affected 
fraction Schedule 1 Schedule 2 Schedule 3
0.25 0.96 1.81 2.25
0.5 0.82 1.10 3.36
0.75 0.73 0.79 5.21
0.95 0.65 0.62 11.7
SH-SY5Y
Affected 
fraction Schedule 1 Schedule 2 Schedule 3
0.25 2.87 4.65 3.08
0.5 1.55 2.91 2.63
0.75 1.11 2.17 2.86
0.95 0.91 1.96 4.71
T98G
Affected 
fraction Schedule 1 Schedule 2 Schedule 3
0.25 3.55 5.53 3.21
0.5 1.69 2.13 2.80
0.75 1.13 1.36 3.96
0.95 0.92 1.04 11.3
The clonogenic assay was used to construct radiation survival 
curves. SK-N-BE(2c): ionising radiation, 1-2-3 Gy, 0.15 μM 
DSF:Cu, 450 nM gemcitabine; UVW: ionising radiation, 
1-2-3 Gy, 0.1 μM DSF:Cu, 20 nM gemcitabine; SH-SY5Y: 
ionising radiation, 0.5-1-1.5 Gy, 0.05 μM DSF:Cu, 40 nM 
gemcitabine; T98G: ionising radiation, 1-2-3 Gy, 1 μM 
DSF:Cu, 50 nM gemcitabine. Combination index analysis was 
carried out to evaluate the nature of the interaction between 
ionising radiation, DSF:Cu and gemcitabine following 
administration schedules 1, 2 and 3.
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studies by suggesting an alternative mechanism by 
which gemcitabine enhances DSF:Cu toxicity, namely 
the targeting, by gemcitabine, of S phase cells which are 
resistant to radiosensitisation by DSF:Cu.
Clonogenic cell kill achieved by the combined 
treatment consisting of DSF:Cu and ionising radiation 
was enhanced by pre-administration or subsequent 
administration of gemcitabine in SK-N-BE(2c), UVW, 
SH-SY5Y and T98G cells. However, the simultaneous 
treatment with gemcitabine, DSF:Cu and ionising 
radiation resulted in enhanced clonogenic cell kill in 
SK-N-BE(2c) cells, but not in UVW, SH-SY5Y and 
T98G cells. Gemcitabine toxicity to S phase cells 
depends on its incorporation into DNA and DSF:Cu 
inhibits DNA synthesis. This may explain the failure of 
gemcitabine to enhance the efficacy of the combination 
treatment consisting of ionising radiation and DSF:Cu 
when administered simultaneously. Furthermore, it 
has been suggested that gemcitabine exerts cytotoxic 
actions in S phase by virtue of binding to critical thiols 
of ribonucleotide reductase [19]. Since DSF:Cu also 
interacts with thiols [18, 53], the competition for these 
binding sites may hinder enhancement of treatment 
efficacy.
Our observation of modulation of cell cycle 
progression by DSF:Cu suggested that enhancement 
of the efficacy of DSF:Cu combined with ionising 
radiation may be achieved through the application 
of cytotoxic drugs acting preferentially on cells in S 
phase. Indeed, decreased clonogenic survival was 
Figure 6: The effect of drug administration according to schedules 2 and 3 on clonogenic survival of SK-N-BE(2c) and 
UVW cells. (A, C) Schedule 2 consisted of pre-treatment of cells with DSF:Cu for 8 h, with irradiation at the commencement of exposure 
to DSF:Cu, immediately followed by treatment with gemcitabine for 24 h. Data are means ± SEM, n=3. (B, D) Schedule 3 consisted of 
simultaneous treatment of cells with gemcitabine for 24 h and DSF:Cu for 8 h, with irradiation at the commencement of drug treatment. 
Data are means ± SEM, n=3.
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obtained by the inclusion of the nucleoside analogue 
gemcitabine with DSF:Cu and ionising radiation 
treatments. However, the radiosensitising mechanism 
of DSF:Cu deserves further study. In particular, critical 
thiols in effectors of DNA repair, cell cycle checkpoint 
and other pathways linked to the cellular response to 
ionising radiation are possible targets for DSF:Cu-
induced radiosensitisation. Recently, DSF:Cu treatment 
has been associated with decreased expression of genes 
involved in DNA repair [31]. The knowledge of the 
radiosensitising mechanism of DSF:Cu could be used 
to refine combination treatments and to define cancer 
patient sub-groups most likely to benefit from DSF:Cu 
and ionising radiation therapy.
It is noteworthy that the repurposing of well-
established drugs such as DSF to cancer treatment has 
received recent interest [59]. In comparison to newly 
designed drugs, the advantages of DSF:Cu include cheaper 
and shorter clinical development due to prior knowledge 
of its favourable toxicological, pharmacokinetic and 
pharmacodynamic profiles. The clinical experience of 
DSF and gemcitabine treatments should facilitate the 
introduction of their combined use in clinical trials of 
radiotherapy.
Figure 7: The effect of antioxidants on clonogenic survival following treatment administration schedule 3. (A) SK-N-
BE(2c) cells were irradiated with 3 Gy and simultaneously treated with 0.15 μM DSF:Cu and 450 nM gemcitabine in the presence of 1 
mM N-acetyl-cysteine (NAC) or 1 mM Tiron. (B) UVW cells were irradiated with 3 Gy and simultaneously treated with 0.1 μM DSF:Cu 
and 20 nM gemcitabine in the presence of 1 mM NAC or 1 mM Tiron. Data are means ± SEM, n=3. The independent t-test was used to 
compare the means of the groups treated in the absence of NAC or Tiron versus those treated in the presence of NAC or Tiron. ***P<0.001; 
ns, non-significant.
Figure 8: The summary of the strategy employed to enhance radiosensitisation by DSF:Cu.
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MATERIALS AND METHODS
Cell culture
The neuroblastoma-derived cell lines SK-N-BE(2c) 
and SH-SY5Y and the glioma-derived cell line T98G were 
purchased from the American Type Culture Collection. 
SK-N-BE(2c) cells were maintained in Dulbecco-modified 
Eagle medium supplemented with 15% (v/v) foetal 
bovine serum (FBS, Autogen Bioclear, Wiltshire, UK), 
2 mM L-glutamine and 1% (v/v) non-essential amino 
acids at 37°C in a 5% CO
2
 atmosphere. SH-SY5Y cells 
were maintained in Dulbecco-modified Eagle medium 
supplemented with 10% (v/v) foetal bovine serum FBS 
and 2 mM L-glutamine at 37°C in a 5% CO
2
 atmosphere. 
The glioma-derived cell lines UVW [60] and T98G were 
maintained in minimum essential medium supplemented 
with 10% (v/v) FBS and 2 mM L-glutamine at 37°C in a 
5% CO
2
 atmosphere. Unless otherwise indicated, all cell 
culture reagents were obtained from Thermo Scientific 
(Paisley, UK).
Drug treatment and irradiation procedure
Gemcitabine, DSF, copper chloride, NAC and Tiron 
were purchased from Sigma-Aldrich (St Louis, MO, 
USA). Gemcitabine and DSF were dissolved in DMSO. 
The cells were exposed to a maximum concentration of 0.1 
% (v/v) DMSO. Copper chloride was dissolved in distilled 
water. NAC and Tiron were dissolved in culture medium. 
DSF:Cu treatment consisted of equimolar concentrations 
of DSF and copper in serum-free culture medium in 
order to control for copper concentration [10]. Cells were 
irradiated using an RS225 irradiator (Xstrahl, Surrey, UK) 
at a dose-rate of 1.64 Gy/min. For combination treatment 
consisting of gemcitabine, DSF:Cu and ionising radiation, 
three schedules of treatment administration were assessed 
(Supplementary Figure 2). Schedule 1 consisted of pre-
treatment of cells with gemcitabine for 24 h immediately 
followed by treatment with DSF:Cu for 8 h. The cells were 
irradiated at the commencement of exposure to DSF:Cu. 
Schedule 2 consisted of pre-treatment of cells with 
DSF:Cu for 8 h, with irradiation at the commencement of 
exposure to DSF:Cu, immediately followed by treatment 
with gemcitabine for 24 h. Schedule 3 consisted of 
simultaneous treatment of cells with gemcitabine for 24 h 
and DSF:Cu for 8 h, with irradiation at the commencement 
of drug treatment.
Clonogenic assay
After treatment, the medium was removed and the 
cells were washed twice with phosphate-buffered saline 
(PBS), suspended by treatment with trypsin and counted 
using a haemocytometer. For every treatment, 600 SK-
N-BE(2c), 250 UVW, 1,000 SH-SY5Y and 700 T98G 
cells were seeded in triplicate in 5.3 cm diameter dishes 
(Thermo Scientific, Paisley, UK) and incubated at 37°C in 
5% CO
2
. When the colonies comprised more than 50 cells, 
medium was removed and the colonies were fixed in 50% 
methanol (v/v) in PBS and stained with 1% (v/v) crystal 
violet in PBS before counting.
Isobologram analysis
Isobologram analysis at the 50% level of effect 
was performed in order to determine the nature of the 
interaction between DSF:Cu and ionising radiation 
treatment according to the method of Steel and Peckham 
[61]. Modes IIa and IIb were chosen to define the envelope 
of additivity because it accounts for non-linearity of 
the dose-effect curves for both DSF:Cu and ionising 
radiation. For mode IIa, a series of ionising radiation 
doses that produces a 0, 10, 20, 30, 40 and 50% reduction 
of clonogenicity was calculated using the median effect 
principle, as described previously [62]. This series of 
effects is then used as the initial level of cytotoxicity from 
which the increment of the concentration of DSF:Cu that 
produces a total level of toxicity of 50% was calculated. 
For mode IIb, a series of DSF:Cu concentrations that 
produces a 0, 10, 20, 30, 40 and 50% reduction of 
clonogenicity was calculated. This series of effects is then 
used as the initial level of cytotoxicity from which the 
increment of the ionising radiation dose that produces a 
total level of toxicity of 50% was calculated.
The coordinates of the isoeffect points were determined 
using the ionising radiation survival curves obtained in the 
absence and in the presence of various concentrations of 
DSF:Cu. Firstly, the surviving fractions were plotted against 
the dose of ionising radiation in the absence and in the 
presence of 0, 0.1, 0.2 and 0.3 μM concentrations of DSF:Cu. 
The doses of ionising radiation producing a 50% reduction 
in clonogenicity (IC
50
 value) in the presence of 0, 0.1, 0.2 
and 0.3 μM of DSF:Cu were calculated using the median 
effect principle. The pairs consisting of the IC
50
 value for 
ionising radiation in the presence of a selected concentration 
of DSF:Cu were the coordinates of the isoeffect points at the 
50% level of cytotoxicity. Secondly, the analogous procedure 
is performed using survival curves obtained in response to 
DSF:Cu treatment in the presence of 0, 1, 2 and 3 Gy ionising 
radiation.
If the isoeffect points lay to the left of the envelope 
of additivity, the response was supra-additive. If the 
isoeffect points lay within the envelope of additivity, the 
response was additive. If the isoeffect points lay to the 
right of the envelope of additivity, the response was infra-
additive.
Combination index analysis
When experimental design did not include treatment 
with incremental doses of each component, the nature of 
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the interaction between the components of a combination 
treatment was assessed by the calculation of the combination 
index. The procedure has been described previously [62]. 
Briefly, the median effect equation was used to calculate 
the doses of each component of the combination treatment 
corresponding to a given effect. The dose reduction index 
was then calculated for each agent of the combination by 
dividing the dose within the combination by the dose as a 
single agent that induced the same kill. The combination 
index (CI) was calculated as the sum of the dose reduction 
indices of each component of the combination.
Chymotrypsin-like activity assay
Chymotrypsin-like activity of the proteasome was 
measured using Proteasome-Glo™ Chymotrypsin-Like, 
Trypsin-Like and Caspase-Like Cell-based Assay kit 
(Promega, US). Exponentially growing cells were treated 
in 96-well plates with DSF:Cu for 8 h at 37°C and 5% CO
2
. 
The cells were then washed with PBS and resuspended in 
100 μl of PBS and exposed to the manufacturer’s buffer 
containing luciferase and the proteasome substrate Suc-
LLVY-luciferin. The luminescent signal, which was a 
measure of proteasomal activity, was measured using a 
Lmax luminometer (Molecule Devices, Sunnyvale, CA).
Cell cycle synchronisation
SK-N-BE(2c) cells were exposed twice to 20 mM 
thymidine for 24 h separated by incubation in thymidine-free 
culture medium for 24 h. UVW cells were exposed twice to 2 
mM thymidine for 15 h separated by incubation in thymidine-
free culture medium for 9 h. At the end of the synchronisation 
procedure, cells were reversibly arrested in early S phase.
Cell cycle analysis
Cells were exposed to 10 μM bromodeoxyuridine 
(BrdU; BD Biosciences, Oxford, UK) for 90 min after 
which cellular monolayers were trypsinized, washed 
twice with PBS and fixed overnight in 70% (v/v) ethanol 
in distilled H
2
O at -20°C. Ethanol was removed by 
centrifugation and resuspension of the pellet in PBS. 
Cells were incubated in 2 M hydrochloric acid (HCl) 
for 20 minutes and then washed with PBS and then with 
PBS buffer containing 0.5% (v/v) Tween-20 (PBST). The 
cells were resuspended in PBS buffer containing 0.05% 
(v/v) Triton X-100 and BrdU antibody (BD Biosciences, 
Oxford, UK) for 20 min at room temperature. Excess 
antibody was removed by centrifugation and resuspension 
in PBST. The cells were then resuspended in 200 μl of 
PBS containing 20 μg/ml of propidium iodide (Sigma-
Aldrich, St Louis, MO, USA) and 200 μg/ml of RNase 
A (Qiagen Ltd., West Sussex, UK) for at least 10 min 
before flow cytometry using a FACScan analyzer (BD 
Biosciences, Oxford, UK). Data were analyzed using the 
FlowJo software (BD Biosciences, Oxford, UK).
Immunoblotting
Whole cellular protein extracts were resolved 
in reducing and denaturing conditions by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis 
for the determination of expression levels of ATM, 
ATM phosphorylated at serine 1981 (ATM1981), CDK1 
and phosphorylated CDK1 at tyrosine 15 (CDK115). 
Proteins were transferred onto polyvinylidene fluoride 
Immobilon-P® membranes (Millipore, UK). Membranes 
were blocked with 7.5% (w/v) milk (CDK1, ATM, 
ATM1981 and β-actin) or bovine serum albumin (CDK115), 
then incubated overnight at 4°C with primary antibodies 
against CDK1 (1:1,000; mouse monoclonal, Millipore, 
UK), CDK115 (1:50,000; rabbit polyclonal, Millipore, 
UK), ATM (1:1,000; mouse monoclonal, Abcam, 
UK), ATM1981 (1:1,000; mouse monoclonal, Novus 
Biologicals, UK) and loading controls β-actin (1:50,000; 
mouse monoclonal, Abcam, UK). Membranes were then 
washed and incubated with horseradish peroxidase-
conjugated secondary anti-mouse antibodies (1:2,000; 
Cell Signalling, UK) or anti-rabbit antibody (1:2,000; 
Santa-Cruz, Heidelberg, Germany) to enable detection 
using enhanced chemolumiscence (Thermo Scientific, 
UK). The densitometric analysis was carried out using 
ImageJ software (National Institute of Health, USA). The 
intensity of the band above background was recorded, 
normalised to that of β-actin and expressed as a fold-
change in comparison with untreated controls.
Circular dichroism
Calf thymus DNA (Sigma-Aldrich, MO, USA) 
was denatured at 90°C for 5 min and allowed to cool and 
anneal at room temperature for 40 min. PBS, ethidium 
bromide (EtBr; Sigma-Aldrich, MO, USA) or DSF:Cu 
were added to 0.05 mg/ml calf thymus-DNA in 1 ml PBS 
prior circular dichroism (CD) spectra acquisition using 
a Jasco-600 spectropolarimeter (Japan Spectroscopic 
Co., Tokyo, Japan). CD spectra (225 to 300 nm) were 
collected using a quartz cell with a path length of 0.5 cm. 
Alternatively, CD spectra (225 to 300 nm) were collected 
from 85 to 20°C at 5°C increments.
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